The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma

A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma

(2018) Tadashi Sakane et al.   Oncotarget

Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer

(2017) Soichiro Funaki et al.   ONCOLOGY REPORTS

Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy

(2016) Panpan Zhang et al.   CANCER SCIENCE

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma

(2016) S. Yokoyama et al.   CLINICAL CANCER RESEARCH

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

(2016) Jacquelyn Smith et al.   Diagnostic Pathology

PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis

(2016) Markus Hecht et al.   EUROPEAN JOURNAL OF CANCER

Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system

(2016) Kelly A Schats et al.   HISTOPATHOLOGY

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

(2016) Sehui Kim et al.   HUMAN PATHOLOGY

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

(2016) Masaki Shimoji et al.   LUNG CANCER

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

(2016) Yuki Katsuya et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

(2015) Yuki Katsuya et al.   LUNG CANCER

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pulmonary Fibroblasts Induce Epithelial Mesenchymal Transition and Some Characteristics of Stem Cells in Non-Small Cell Lung Cancer

(2013) Yasushi Shintani et al.   ANNALS OF THORACIC SURGERY

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity to Chemoradiotherapy in Non-Small Cell Lung Cancer

(2011) Yasushi Shintani et al.   ANNALS OF THORACIC SURGERY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor–β Signaling

(2007) Yasushi Shintani et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY